NasdaqGS:OPK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. More Details


Snowflake Analysis

Fair value with moderate growth potential.


Similar Companies

Share Price & News

How has OPKO Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OPK is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: OPK's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

3.4%

OPK

3.5%

US Biotechs

-1.0%

US Market


1 Year Return

191.7%

OPK

36.8%

US Biotechs

19.6%

US Market

Return vs Industry: OPK exceeded the US Biotechs industry which returned 36.8% over the past year.

Return vs Market: OPK exceeded the US Market which returned 19.6% over the past year.


Shareholder returns

OPKIndustryMarket
7 Day3.4%3.5%-1.0%
30 Day1.1%4.5%2.2%
90 Day5.9%19.2%11.5%
1 Year191.7%191.7%39.0%36.8%22.3%19.6%
3 Year1.8%1.8%30.5%23.6%45.3%35.7%
5 Year-44.8%-44.8%43.9%33.0%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is OPKO Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OPKO Health undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OPK ($4.55) is trading below our estimate of fair value ($15.81)

Significantly Below Fair Value: OPK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OPK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: OPK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OPK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OPK is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is OPKO Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

25.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: OPK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OPK's is expected to become profitable in the next 3 years.

Revenue vs Market: OPK's revenue (1.6% per year) is forecast to grow slower than the US market (10.2% per year).

High Growth Revenue: OPK's revenue (1.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OPK's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has OPKO Health performed over the past 5 years?

-35.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OPK is currently unprofitable.

Growing Profit Margin: OPK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OPK is unprofitable, and losses have increased over the past 5 years at a rate of 35.2% per year.

Accelerating Growth: Unable to compare OPK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: OPK has a negative Return on Equity (-7.02%), as it is currently unprofitable.


Next Steps

Financial Health

How is OPKO Health's financial position?


Financial Position Analysis

Short Term Liabilities: OPK's short term assets ($428.1M) exceed its short term liabilities ($335.9M).

Long Term Liabilities: OPK's short term assets ($428.1M) exceed its long term liabilities ($411.6M).


Debt to Equity History and Analysis

Debt Level: OPK's debt to equity ratio (14.5%) is considered satisfactory.

Reducing Debt: OPK's debt to equity ratio has increased from 6.5% to 14.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OPK has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OPK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is OPKO Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OPK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OPK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OPK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OPK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

Phil Frost (84 yo)

13.83yrs

Tenure

US$1,405,200

Compensation

Dr. Phillip Frost, also known as Phil, M.D., Ph.D., has been Chief Executive Officer of Opko Health, Inc. since March 27, 2007. Dr. Frost serves as the Managing Director and General Partner of Frost Philli...


CEO Compensation Analysis

Compensation vs Market: Phil's total compensation ($USD1.41M) is below average for companies of similar size in the US market ($USD5.00M).

Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Phillip Frost
Chairman & CEO13.83yrsUS$1.41m29.02%
$ 884.7m
Jane Hsiao
Vice Chairman & Chief Technical Officer13.67yrsUS$1.35m4.88%
$ 148.9m
Adam Logal
Senior VP & CFO6.83yrsUS$921.20k0.027%
$ 815.2k
Steven Rubin
Executive VP of Administration & Director13.92yrsUS$1.13m0.86%
$ 26.2m
Rulfo Hernandez
Chief Accounting Officer0.50yrno data0.000010%
$ 304.9
Arie Gutman
President of APIno datano datano data
James DeMarco
Senior Vice President of Pharmaceutical Sales4.75yrsno datano data
Thomas Nusbickel
Chief Commercial Officer4.67yrsno datano data
Akhtar Ashfaq
Senior Vice President of Clinical Research & Development and Medical Affairs3.83yrsno datano data
Jon Cohen
Senior VP & Director2yrsno data0.011%
$ 341.1k
Jane Wood
Chief Legal Officer of Bio-Reference Laboratoriesno datano datano data
David Okrongly
President of OPKO Diagnostics7.5yrsno datano data

6.8yrs

Average Tenure

63yo

Average Age

Experienced Management: OPK's management team is seasoned and experienced (6.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Phillip Frost
Chairman & CEO13.83yrsUS$1.41m29.02%
$ 884.7m
Jane Hsiao
Vice Chairman & Chief Technical Officer13.67yrsUS$1.35m4.88%
$ 148.9m
Steven Rubin
Executive VP of Administration & Director13.92yrsUS$1.13m0.86%
$ 26.2m
Jon Cohen
Senior VP & Director2yrsno data0.011%
$ 341.1k
Richard Pfenniger
Lead Independent Directorno dataUS$66.50k0.041%
$ 1.3m
Richard Lerner
Independent Director & Member of Scientific Advisory Boardno dataUS$51.00k0.030%
$ 904.8k
John Paganelli
Independent Director17.08yrsUS$56.00k0.055%
$ 1.7m
Roger Kornberg
Member of Scientific Advisory Boardno datano datano data
Lin-Tsing Yu
Independent Director11.75yrsUS$41.00k0.0099%
$ 302.4k
Thomas Kodadek
Member of Scientific Advisory Boardno datano datano data
Tahir Ahmed
Member of Scientific Advisory Boardno datano datano data
Robert Fishel
Independent Director2.75yrsUS$48.92k0.62%
$ 18.7m

13.7yrs

Average Tenure

73yo

Average Age

Experienced Board: OPK's board of directors are seasoned and experienced ( 13.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OPK insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

OPKO Health, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OPKO Health, Inc.
  • Ticker: OPK
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.049b
  • Shares outstanding: 670.00m
  • Website: https://www.opko.com

Number of Employees


Location

  • OPKO Health, Inc.
  • 4400 Biscayne Boulevard
  • Miami
  • Florida
  • 33137
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XCYDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1995
OPKNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1995
OPK *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 1995
OPKTASE (The Tel-Aviv Stock Exchange)YesCommon StockILILSNov 1995
0KCSLSE (London Stock Exchange)YesCommon StockGBUSDNov 1995

Biography

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostic...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/17 00:24
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.